Bioton S.A. Total Liabilities
Bioton S.A. total liabilities. Based on the latest financial reports, Bioton S.A. (BIO) has total liabilities worth zł170.59 Million PLN (≈ $46.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BIO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Bioton S.A. (2005–2025)
Total liabilities of Bioton S.A. from 2005 to 2025. This chart illustrates how Bioton S.A.'s total liabilities have evolved over time, based on quarterly financial data. Check BIO financial resilience to evaluate the company's liquid asset resilience ratio.
Bioton S.A. Competitors by Total Liabilities
The table below lists competitors of Bioton S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Artiva Biotherapeutics, Inc. Common Stock
NASDAQ:ARTV
|
USA | $19.64 Million |
|
SHEPHERD NEAME P. CONS.
F:43Y
|
Germany | €183.58 Million |
|
Lumi Gruppen AS
OL:LUMI
|
Norway | Nkr551.59 Million |
|
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
|
India | Rs5.44 Billion |
|
Sarla Performance Fibers Limited
NSE:SARLAPOLY
|
India | Rs-5.15 Billion |
|
Lexinfintech Holdings Ltd
NASDAQ:LX
|
USA | $10.62 Billion |
|
Electrotherm (India) Limited
NSE:ELECTHERM
|
India | Rs21.28 Billion |
|
China Aluminum International Engineering Corporation Limited
F:4AI
|
Germany | €31.41 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Bioton S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bioton S.A. balance sheet assets.
Liquidity & Leverage Metrics
Bioton S.A. Total Liabilities Ratios Explained
Bioton S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioton S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioton S.A. (2005–2025)
The table below shows the annual total liabilities of Bioton S.A. from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | zł170.59 Million ≈ $46.95 Million |
-16.21% |
| 2024-12-31 | zł203.59 Million ≈ $56.03 Million |
-5.69% |
| 2023-12-31 | zł215.87 Million ≈ $59.41 Million |
+5.68% |
| 2022-12-31 | zł204.27 Million ≈ $56.22 Million |
-15.75% |
| 2021-12-31 | zł242.45 Million ≈ $66.73 Million |
-2.03% |
| 2020-12-31 | zł247.46 Million ≈ $68.11 Million |
-17.35% |
| 2019-12-31 | zł299.42 Million ≈ $82.40 Million |
+0.74% |
| 2018-12-31 | zł297.23 Million ≈ $81.80 Million |
-19.39% |
| 2017-12-31 | zł368.72 Million ≈ $101.48 Million |
-23.40% |
| 2016-12-31 | zł481.36 Million ≈ $132.48 Million |
+8.56% |
| 2015-12-31 | zł443.41 Million ≈ $122.03 Million |
-12.77% |
| 2014-12-31 | zł508.32 Million ≈ $139.90 Million |
+0.52% |
| 2013-12-31 | zł505.69 Million ≈ $139.17 Million |
-12.62% |
| 2012-12-31 | zł578.69 Million ≈ $159.26 Million |
-9.53% |
| 2011-12-31 | zł639.67 Million ≈ $176.05 Million |
+55.34% |
| 2010-12-31 | zł411.78 Million ≈ $113.33 Million |
-21.54% |
| 2009-12-31 | zł524.85 Million ≈ $144.45 Million |
-36.54% |
| 2008-12-31 | zł827.09 Million ≈ $227.63 Million |
+25.44% |
| 2007-12-31 | zł659.36 Million ≈ $181.47 Million |
+259.27% |
| 2006-12-31 | zł183.53 Million ≈ $50.51 Million |
+78.69% |
| 2005-12-31 | zł102.70 Million ≈ $28.27 Million |
-- |
About Bioton S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more